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Abstract
IMPORTANCE Some of the unexplained heritability of Alzheimer disease (AD) may be due to rare
variants whose effects are not captured in genome-wide association studies because very large
samples are needed to observe statistically significant associations.
OBJECTIVE To identify genetic variants associated with AD risk using a nonstatistical approach.
DESIGN, SETTING, AND PARTICIPANTS Genetic association study in which rare variants were
identified by whole-exome sequencing in unrelated individuals of European ancestry from the
Alzheimer’s Disease Sequencing Project (ADSP). Data were analyzed betweenMarch 2017 and
September 2018.
MAINOUTCOMES ANDMEASURES Minor alleles genome-wide and in 95 genes previously
associated with AD, AD-related traits, or other dementias were tabulated and filtered for predicted
functional impact and occurrence in participants with AD but not controls. Support for several
findings was sought in a whole-exome sequencing data set comprising 19 affected relative pairs from
Utah high-risk pedigrees and whole-genome sequencing data sets from the ADSP and Alzheimer’s
Disease Neuroimaging Initiative.
RESULTS Among 5617 participants with AD (3202 [57.0%] women; mean [SD] age, 76.4 [9.3] years)
and 4594 controls (2719 [59.0%] women; mean [SD] age, 86.5 [4.5] years), a total of 24 variants
with moderate or high functional impact from 19 genes were observed in 10 or more participants
with AD but not in controls. These variants included amissensemutation (rs149307620 [p.A284T],
n = 10) in NOTCH3, a gene in which coding mutations are associated with cerebral autosomal-
dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), that was also
identified in 1 participant with AD and 1 participant with mild cognitive impairment in the whole
genome sequencing data sets. Four participants with AD carried the TREM2 rs104894002 (p.Q33X)
high-impact mutation that, in homozygous form, causes Nasu-Hakola disease, a rare disorder
characterized by early-onset dementia andmultifocal bone cysts, suggesting an intermediate
inheritancemodel for themutation. Compared with controls, participants with AD had a significantly
higher burden of deleterious rare coding variants in dementia-associated genes (2314 vs 3354
cumulative variants, respectively; P = .006).
CONCLUSIONS ANDRELEVANCE Different mutations in the same gene or variable dose of a
mutationmay be associated with result in distinct dementias. These findings suggest that minor
differences in the structure or amount of protein may be associated with in different clinical
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Question Can rare genetic variants for
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Abstract (continued)
outcomes. Understanding these genotype-phenotype associations may provide further insight into
the pathogenic nature of themutations, as well as offer clues for developing new therapeutic targets.
JAMA Network Open. 2019;2(3):e191350. doi:10.1001/jamanetworkopen.2019.1350
Introduction
Alzheimer disease (AD) is the most common type of dementia and affects an estimated 5.7 million
individuals in the United States, with the number projected to rise to 14 million by 2050.1
Susceptibility to AD is highly heritable (h2 = 58%-79%),2 but only about one-third of the genetic
component is accounted for by common variants discovered through genome-wide association
studies.2 Some of the unexplained heritability of ADmay be due to rare variants, which remain
challenging to discover in genomic studies because of statistical power limitations, despite large
sample sizes.3 Genome-wide searches have identified AD associations with rare variants in relatively
few genes, including TREM2,AKAP9,UNC5C, ZNF655, IGHG3, and CASP7,4-8 andmethods to evaluate
rare variants are still under development.3 We applied a strategy focused on rare variants occurring
only in cases to identify and characterize additional high-penetrance risk variants in AD that would be
otherwise undetected in analyses that do not render results when a variant is not observed in the
control group.
Methods
Study Population andData Pipeline
The Alzheimer’s Disease Sequencing Project (ADSP) performedwhole-exome sequencing (WES) on
DNA samples obtained from participants of non-Hispanic European ancestry (EA) and a group of
Caribbean Hispanic individuals that was deemed too small for inclusion in this study. A total of 5617
participants with ADmet National Institute of Neurological and Communicative Diseases and Stroke/
Alzheimer’s Disease and Related Disorders Association criteria for possible, probable, or definite AD
after clinical and/or neuropathologic examination9 and 4594 controls were cognitively normal. The
ADSP participants were selected using a risk score based on age, sex, and APOE ε4 carrier status to
maximize cases most likely to have AD risk variants and controls most likely to have AD protective
variants. Sample characteristics are provided in eTable 1 in the Supplement.
Written informed consent was obtained from all participants who were 60 years or older or
from their authorized legal representative. This study was approved by the Boston University
Institutional Review Board. Data were analyzed betweenMarch 2017 and September 2018. This
study followed the Strengthening the Reporting of Genetic Association Studies (STREGA) reporting
guideline.
Gene Selection andVariant-Filtering Pipeline
Rare variants were analyzed under 2 different schemes: one considering all genes in the genome and
another focused on genes for which there was prior evidence linking them to AD, AD-related
endophenotypes, or other disorders in which adult-onset dementia was the cardinal feature.
Selection of genes for the latter analysis scheme (listed in eTable 2 in the Supplement) was based on
a review of the literature and required either genome-wide significant association findings or
generally accepted functional evidence. Details about DNA sequencing, data quality control, and
variant selection and annotation are provided in the eMethods and eTable 3 in the Supplement. The
study design is illustrated in eFigure 1 in the Supplement.
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Rare Variant Analysis in an Independent Data Set
To extend and enhance the discovery of novel associations, we evaluatedWES data obtained from 19
AD-affected first- or second-cousin pairs identified in the Utah Population Database belonging to a
pedigree with a statistical excess of AD risk. These pedigrees are genealogically independent at least
as far back as the early 1800s. Details of the Utah Population Database, case classification, and
identification of high-risk pedigrees have been published elsewhere.18 A series of steps that included
filters for sharing among affected relatives, frequency in several public next-generation sequencing
databases, pathogenicity, and relevance to AD pathologic factors resulted in 130 variants exomewide
for further evaluation (eMethods in the Supplement).
Statistical Analysis
HaplotypeAnalysis
PLINKwas used to find common single-nucleotide polymorphisms (SNPs) near the rare variant of
interest within a specified kilobase (kb) window. The wildcard option was used to infer haplotypes
and estimate haplotype frequencies.10 Haploview was used to visualize regional linkage
disequilibrium and confirm haplotypes and frequencies among different SNP combinations using
multimarker haplotype association tests.11
Protein HomologicModeling and PathwayAnalysis
Protein homologic modeling was performed for several high-impact variants in NOTCH3with
BLAST-P, version 2.7.1,12 SWISS-MODEL, SMTL version 2019-02-13 (PDB release 2019-02-08),13 and
Maestro, version 11.2 software.14 Additional details of the modeling procedures are provided in the
eMethods in the Supplement. A high-confidence (confidence score >0.7) human protein-protein
interaction network was then created with version 10 of the STRING database for NOTCH3 and its
ligand JAG1.15 The set of genes forming the protein network was tested for gene-set enrichment
using Protein Analysis Through Evolutionary Relationships pathways and the Fisher exact test with
false discovery rate multiple test correction.16
Estimation of Burden of Rare Variants
A gene-set test was performed to evaluate the burden of high- and moderate-impact mutations in
the set of AD- or dementia-related genes among participants with AD compared with controls.
Logistic regressionmodels, including covariates for sex, age, sequencing center, and principal
components of ancestry, were evaluated using the Combined andMultivariate Collapsing method17
in R, version 3.5.0 (R Foundation). Findings were considered significant at 2-tailed P < .05.
Results
After performing data-filtering steps, 5617 participants with AD (3202 [57.0%] women; mean [SD]
age, 76.4 [9.3] years) and 4594 controls (2719 [59.0%] women; mean [SD] age, 86.5 [4.5] years)
remained for analysis.
Rare Variants inNOTCH3
Evaluation of high- andmoderate-impact rare variants in genes that were previously established as
genetically or functionally associated with AD or dementia revealed amissensemutation in NOTCH3
(rs149307620; p.A284T) thatwas present in 10AD cases, but no controls (eTable 4 in the Supplement).
This variant is rare in EAs (minor allele frequency [MAF], 0.0005)19 and was verified by Sanger
sequencing in 8 of these participants for whomDNAwas available. Because several other high- or
moderate-impact NOTCH3mutations have been associated with cerebral autosomal-dominant
arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a diagnostically distinct
disorder marked by severe headaches in young adulthood followed by strokes and dementia later in
life,20we sought clinical and autopsy data from the participantswith ADwith the rs149307620mutation
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to determinewhether they are enriched for cerebrovascular risk factors. Neuropathologic information
that was available for one of these participants revealedmoderate atherosclerosis but no
arteriosclerosis, lacunes, ormicroinfarcts, which are hallmarks of CADASIL (eTable 5 in the Supplement).
Autopsy also confirmed the presence of AD abnormalities (Consortium to Establish a Registry
for Alzheimer’s Disease [CERAD] neuritic plaques, moderate; CERAD diffuse plaques, moderate; and
Braak neurofibrillary degeneration, stage VI). Themean (SD) age at symptom onset for the 10
NOTCH3mutation carriers was 80.5 (6.7) years, which was similar to that for the entire sample of
ADSP EA cases (80.9 [9.1] years) and greater than age at onset of cognitive impairment among
individuals with CADASIL (usually <50 years). None of the NOTCH3mutation carriers had a history of
clinical strokes (although 1 carrier hadmultiple infarcts shown onmagnetic resonance imaging and a
history of diabetes and cardiovascular disease) and all had prominent memory impairment as the
initial presentation with a progressive course. One otherNOTCH3mutation (rs114447350; p.P2074Q)
was observed in 4 participants with AD but not in controls (eTable 4 in the Supplement). Unlike
rs149307620, this variant is not rare in EAs (MAF, 0.024) or in persons of African ancestry (MAF,
0.091),21 suggesting it is unlikely to be pathogenic.
Because rs149307620 is rare, we investigated the possibility that this mutation occurred once
or only a few times by performing a haplotype analysis with common SNPs. This analysis revealed a
5-SNP haplotype with a frequency of 15% in the participants with AD and 14% in controls that is
common to all 10 cases with theNOTCH3mutation (eFigure 2 in the Supplement). Themean pairwise
identical-by-descent (IBD) sharing for the 10mutation carriers (mean [SD] πˆ = 0.028 [0.025]) is slightly
larger than themean pairwise IBD sharing within the rest of ADSP sample (mean [SD] πˆ = 0.013
[0.026]), indicating that the carriers are notmore closely related to each other than to all participants.
Taken together, these results suggest that themutation in these participants originated in a common
ancestor who livedmany generations ago.
To investigate the possibility that themutation carriers belong to a particular subpopulation, we
plotted the first 2 principal components of ancestry that were derived previously for the entire
sample7 and observed that 8 of the 10mutation carriers were clustered in a distinct minor portion of
the sample (eFigure 3 in the Supplement). Analysis ofmitochondrial DNA variants revealed thatmost
individuals in this cluster had mitochondrial haplogroups K1a1b1a or K1a9 that are common among
Ashkenazi Jewish individuals.22 Moreover, NOTCH3mutations carriers accounted for 4.0% of the
participants with ADwho have either the K1a1b1a or K1a9 haplogroup. The proportion of mutation
carriers in this cluster was significantly greater among participants with AD (8 of 358 [2.2%]) than
controls (0 of 337) (Z = 2.76, P = .006). The frequency of the rs149307620mutation is about 25 times
higher in Ashkenazi Jewish individuals (MAF, 0.0046) compared with other EA groups (MAF,
0.00019).19
Analysis of the 130 variants that met the filtering criteria in the 19 affected cousin pairs from the
Utah high-risk pedigrees provided additional support for a role of NOTCH3 in AD. Both affected
individuals in 1 family who are half-first cousins had 2 rareNOTCH3missensemutations—rs141402160
(p.G248A) and rs140914494 (p.A198E)—each with a population frequency of 0.0002.20 Review of
available clinical and family history information for this family did not indicate findings consistent with
CADASIL in the probands or relatives. The pedigree of the carriers of the rs141402160 and rs140914494
mutations includes 7 additionalmemberswhohadADor dementia listed ondeath certificates (eFigure 4
in the Supplement). All but 1 of the individuals in the line of descent from the common ancestor of the
pair died before age 60 years, prior to the age at onset of AD in the cases. An affected cousin pair in an
independent family had theNOTCH3missense variant rs112197217 (p.H1133Q), which has a frequency
of 0.010 in EAs,21 but is rarer in other populations (eFigure 5 in the Supplement). The evidence of AD
among other relatives in this family was inconclusive.
To further distinguish which of the 5 NOTCH3 variants identified in the ADSPWES sample and
Utah families may be related to AD, we screened for these variants in whole-genome sequence
(WGS) data obtained from amultiethnic sample of unrelated 1432 participants with AD and 1660
controls in the ADSP Extension Study, 550 participants with AD and 283 controls in the ADSP
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multiethnic Family Study,23 and 809 participants in the Alzheimer’s Disease Neuroimaging Initiative
Study (239 participants with AD, 321 participants with mild cognitive impairment, 249 controls).24
Characteristics of participants in these data sets are provided in eTable 6 in the Supplement. The
minor alleles for rs11219217 (n = 70) and rs114447350 (n = 286) were observed appreciably in
participants with AD, participants withmild cognitive impairment, and controls of multiple ethnicities
suggesting that they are not associated with AD risk. The rs149307620 variant was found in 1 AD case
(age at onset, 89 years) and 1 mild cognitive impairment case (age at onset, 76 years), but not in
controls. The rare rs141402160 and rs140914494 variantswere not detected in any of theWGS samples.
Protein modeling showed that the rs149307620 mutation is located in the EGF repeat region
between EGF10 and EGF11 andmore precisely in the EGF calcium binding (EGF_CA) domain, near the
Jagged-1 (JAG1)-NOTCH3binding site.25Modeling predicted that themajor allele for rs149307620 results
in wild-type notch-3 with a corresponding amino acid alanine (Figure 1A). The alanine side chain is
nonpolar and would not be predicted to have any intraprotein or interprotein interactions. Theminor
allele for rs149307620 results inmutant notch-3with a corresponding amino acid threonine (Figure 1B).
Threonine is polar and will form hydrogen bonds where possible with itself or with a polar histidine
nearby in NOTCH3. This action then alters the backbone conformation in this region in themodel and
allows additional interactionswith a polar arginine at the site of JAG1-NOTCH3 binding (Figure 1C). These
results suggest that themutant Notch-3 causes greater interaction with the ligand, possibly changing
downstream processes. The other AD-associatedNOTCH3mutations, rs141402160 and rs140914494,
also involve either the gain or loss of an alanine. In both instances, the mutation change leads to
increased polarity and hydrogen bonding with possible increased interactions to a greater or lesser
extent that observed with rs149307620.
Unlike the rs149307620 and rs141402160mutations, but similar to the rs140914494mutation,
most of themore than 25 reported distinctNOTCH3mutations causing CADASIL are located in exons
3 and 4 (Table 1).26 However, 1 CADASIL-associated variant, rs137852641, is a missensemutation in
codon 332 in exon 6, resulting in the replacement of an arginine residue with a cysteine27 that is
proximate to rs149307620 (codon 284 in exon 6) (Figure 2).
To further explore the biological functions and pathways for NOTCH3 in AD, a high-confidence
protein-protein interaction network was constructed including NOTCH3 and JAG1. The resulting
Figure 1. Notch-3 ProteinModel Highlighting Position of the Alzheimer Disease–Associated Single-Nucleotide
Polymorphism rs149307620 (p.A284T)
Wild-type alleleA Mutant alleleB Binding of notch-3 to JAG1C
Predictedmodel for wild-type allele with alanine at
mutation site (A), mutant allele with threonine at
mutation site (B), and binding of notch-3 (red) to JAG1
ligand (yellow) (C). Possible hydrogen bonding that
would likely cause greater interaction with the ligand
is displayed.
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30-gene interaction network contains several AD-related genes, including BACE1, PSEN1, PSEN2, and
APP (eFigure 6 in the Supplement). Gene-set enrichment analysis revealed that the network genes
were significantly enriched in the Notch signaling pathway (P = 6.48 × 10−49), angiogenesis
(P = 1.61 × 10−12), and 2 AD-related pathways involving secretase-mediated amyloid precursor
protein cleavage (P = 3.50 × 10−16) and presenilin γ-secretase complex (P = 5.78 × 10−26) (Table 2).
TREM2Q33X
We also identified the high-impact TREM2 rs104894002 (p.Q33X) mutation in 4 of 5617 (0.071%)
participants with AD (eTable 4 in the Supplement), a frequency that is slightly lower than that observed
in a TREM2 sequencing study of participants with AD and controls in 2013 (2 of 1084 [0.17%]
participants with AD).4 Because this mutation in a homozygous state causes Nasu-Hakola disease, a
Table 1.NOTCH3MutationsWith Predicted Functional Impact on AD Risk
SNP Position (chr 19)a Exon GnomAD Frequency Protein Position Residue Change Observed Mutation Carriers
rs140914494 15 192 046 4 0.00003 198 Ala>Glu AD-affected relative pair
rs141402160 15 191 804 5 0.00005 248 Gly>Ala AD-affected relative pair
rs149307620 15 191 610 6 0.00029 284 Ala>Thr 11 Participants with AD, 1 participant with MCI
Abbreviations: AD, Alzheimer disease; GnomAD, Genome Aggregation Database; MCI,
mild cognitive impairment; SNP, single-nucleotide polymorphism.
a Chromosome position according to GRCh38.p12 assembly.
Figure 2. Homologous ProteinModeling of Cerebral Autosomal-Dominant ArteriopathyWith Subcortical
Infarcts and Leukoencephalopathy (CADASIL)NOTCH3 rs137852641 (p.R332C)Mutation
Wild-type alleleA Mutant alleleB
ARG 32 CYS 32
Predictedmodel for wild-type allele with arginine at
themutation site (A) andmutant allele with cysteine at
themutation site (B). Gain of a cysteine residue
disrupts disulfide bonding within the protein, affecting
overall protein structure.
Table 2. Gene-Set Enrichment Analysis of NOTCH3/JAG1 Protein-Protein Interaction Network
PANTHER Pathway No. of Genes Annotated to Pathway No. of Genes in Network Expected P Valuea Fold Enrichment Unadjusted P Value FDR
Notch signaling 42 22 .06 >100 3.98 × 10−51 6.48 × 10−49
Presenilin 123 14 .18 >100 7.09 × 10−28 5.78 × 10−26
Amyloid secretase 69 7 .10 >100 8.59 × 10−18 3.50 × 10−16
Angiogenesis 173 10 .25 40.54 4.92 × 10−14 1.61 × 10−12
Abbreviations: FDR, false discovery rate; PANTHER, Protein Analysis Through
Evolutionary Relationships classification system.
a Expected probability of observing at least x number of genes out of the total number
of genes in the PANTHER list annotated to a particular pathway, given the proportion of
genes in the referenceHomo sapienswhole genome that are annotated to
that pathway.
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rare autosomal-recessive disorder characterized by early-onset dementia andmultifocal bone cysts,28
we evaluated clinical data obtained from the 4 TREM2Q33Xmutation carriers to assess potential
pleiotropic effects (eTable 7 in the Supplement). All of these participants met the criteria for probable
AD and none had reported bone cysts or unusual behavioral symptoms.
Other RareMutations
A total of 32moderate- or high-impact variants in 24 previously established genes for AD or other
dementias were each observed in 4 or more participants with AD and no controls (eTable 4 in the
Supplement). Five of these variants were previously reported as associated with AD and include
missensemutations in PSEN1 (rs63749824/p.A75V [n = 7]29; rs63750592/p.R35Q [n = 4]),30 SORL1
(rs139710266/p.Y391C [n = 5]),31 andMAPT (rs63750424/p.R741W [n = 4]),32 and a stop-gainmutation
in ABCA7 (rs145987355/ p.E1679X [n = 4]).33 Genome-wide, 24 variants in 19 genes with moderate
to high functional impact were observed in 10 or more participants with AD but absent in controls
(eTable 8 in the Supplement). Further examination of the genes represented by multiple variants
revealed that 10 participants had 3ABCD4missense variants (rs57773157/p.G248, rs34992370/p.V172I,
rs58272575/p.G59R) that co-occur in a rare 8-SNP haplotype spanning 12.9 kbwith a frequency of 0.3%
in cases and 0% in controls (eFigure 7A in the Supplement). Another 10 participants had 2 CELSR1
missense variants (rs61741871/p.2983A and rs75983687/p.2703M), and 8 of these participants also
had 2GTSE1missense variants (rs34404175/p.A219V and rs35503220/p.A293A). One participant was
homozygous for all 4 variants. The participants who had these CELSR1 and GTSE1 variants share a rare
12-SNP haplotype spanning 77.6 kbwith a frequency of 0.1% in cases and 0.1% in controls (eFigure 7B
in the Supplement). Estimates of IBD sharing for the 10 participants with the ABCD4 variants were only
slightly higher (mean [SD] πˆ = 0.015 [0.028]) and for the 8 participants with AD and the CELSR1 and
GTSE1 variants (mean [SD] πˆ = 0.008 [0.015]) were lower than genome-wide IBD sharing, suggesting
that they are not more closely related to each other than to all participants. There were few common
SNPs in the 500-kb region including the rare ABCD4 variants, suggesting high-sequence conservation
in this region.
To identify additional genes that may have overrepresentation of deleterious AD-related
variants, we filtered genes that contained at least 3 distinct variants, each occurring in at least 5
participants with AD but absent in controls (eTable 9 in the Supplement). The ABCD4
rs61744947/p.P2983A variant appears on the same haplotype containing the other 3 ABCD4 variants.
Three LAMC3 variantswere observed in the same7participants. TTNhad the greatest number of distinct
variants (n = 6) that were observed in participants with AD only. Genome-wide, 9 genes not previously
associatedwith AD contained a high functional impact variant that was present in at least 7 participants
with AD but absent in controls (eTable 10 in the Supplement).
Rare Variant Burden
To test if AD is associated with greater burden of rare deleterious variants, gene burden tests were
performed for models including high-impact variants and high- and moderate-impact variants for
MAF of 0.01 or lower andMAF of 0.5 or lower in genes previously associated with AD risk, AD-related
traits, or other dementias (Table 3). These analyses showed that participants with AD had a
significantly higher burden of moderate- and high-impact rare deleterious variants in this group of
genes compared with controls (2314 vs 3354 cumulative variants, respectively; P = .006).
Table 3. Rare Variant Burden for Established Alzheimer Disease Genes
Model β (SE) P Value
High impact, MAF ≤ 0.01 0.005 (0.166) .98
High/moderate impact, MAF ≤ 0.01 0.062 (0.023) .006
High impact, MAF ≤ 0.05a 0.005 (0.166) .98
High/moderate impact, MAF ≤ 0.05a 0.061 (0.022) .006
Abbreviation: MAF, minor allele frequency.
a No deleterious variants with MAF between 0.01 and
0.05 were observed in this group of genes.
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Discussion
We identified several rare variants that have a high probability of damage to protein structure and
may increase AD risk. These variants were not detected in previous analyses of the same ADSPWES
data set that were agnostic with respect to functional impact of the variants and conducted using
current statistical testing approaches.7 Our focus on variants observed in participants with AD but
not controls yielded results that are often undetected by traditional genetic associationmethods that
cannot evaluate empty cells, regardless of sample size or frequency of variants among cases. Several
of our top-ranked results confirm previously identified AD associationswith rare variants, including
PSEN1 rs6374982429 and rs63750592,30 SORL1 rs139710266,31MAPT rs63750424,32 and ABCA7
rs145987355,33 which suggest that novel findings identified by our approachmay be robust. Two of
our novel findings offer additional evidence of shared genetic mechanisms between AD and other rare
dementia syndromes, namely CADASIL and Nasu-Hakola disease. Our study also suggests that
participants with AD have a significantly higher burden of deleterious rare coding variants in known
AD, AD-related, or other dementia genes comparedwith controls. This observation generalizes previous
findings in SORL1,31,34,35MAPT,32,36 TREM2,4,37,38 andABCA733,39-41 that both common and rare variants
in the same genemay independently contribute to AD risk.
We observed the rareNOTCH3 rs149307620 allele in 11 participants with AD and 1 participant with
mild cognitive impairment, but not in controls, in the combinedADSPWES, ADSPWGS, andAlzheimer’s
Disease Neuroimaging InitiativeWGS data sets. Themost remarkable finding from analysis of the Utah
high-risk pedigreeWES data set was rare NOTCH3 rs140914494 and rs141402160 alleles in a pair of
affected half first-cousins. Thesemutations in exons 4 (rs140914494), 5 (rs141402160), and 6
(rs149307620) are located in the JAG1 binding site and involve the gain or loss of an alanine residue
(Table 1). Based on this evidence alone, it is unclear whether one or both of the rs140914494 and
rs141402160mutations, which are likely in cis given their probable inheritance from a single common
ancestor, have a role in AD. In contrast, the rs114447350 and rs112197217 variants are located near the
end of the coding sequence (exons 33 and 21, respectively) andmay be clinically benign42 and thus
unlikely to be causally related to AD.Many otherNOTCH3 variants have been associatedwith CADASIL
that typically replace the wild-type amino acid with a cysteine residue or replace a highly conserved
cysteine residue with another amino acid,20,26,27 although there are several exceptions.43 Available
clinical and autopsy data for the individuals withNOTCH3mutationswere consistent with the diagnosis
of AD and not CADASIL. Our proteinmodeling demonstrated that the AD-associatedNOTCH3mutations
in exons 4 to 6 result in quantitative changes in hydrogen bonding causing increased ligand interaction,
whereas CADASILNOTCH3mutations lead to qualitative changes involving disrupted disulfide bonding
that affect overall protein structure and receptor maturation and differ with respect to their
consequences on both ligand binding and ligand-induced signaling.26,27
Our protein-protein interaction network and gene-set enrichment analyses demonstrated that
NOTCH3 is associatedwith AD pathways and biological processes. Notch-3 signaling can be triggered
by both delta-JAG-type ligands and requires ADAM10 and presenilin-1 or -2, making it part of the
AD-related presenilin pathway.44 Previous studies showed that JAG1-Notch signaling and
subsequent hippocampal neurogenesis and astrogenesis are regulated by cleavage by BACE1, a
promising AD drug target.44 This process, which is more active during early development and
decreases in adulthood, affects normal neuronal development and alters neurogenesis and thus can
have long-term effects.44 In addition, Notch-3 is a substrate for γ-secretase (presenilin) inhibition,
which, when dysregulated, can cause misprocessing of the amyloid precursor protein resulting in
accumulation of the toxic amyloid-β peptide.45
To our knowledge, these collective genetic and bioinformatics findings provide the strongest
possible pathogenic link to date between NOTCH3 and AD. A previous study reported an association
of AD with a distinct NOTCH3mutation (p.R1231C) in a Turkish family46; however, this variant was
detected in only 1 affectedmember and there is conflicting information about its pathogenicity.47
Sassi et al48 tested the hypothesis that genes associated with mendelian adult-onset leukodystrophy
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are also associated with AD in a sample including 332 sporadic participants with AD and 676 controls
and found a significant gene-based association withNOTCH3, a result driven primarily by a common
synonymous coding variant.
The TREM2Q33Xmutation that was observed in 4 participants with AD in our sample and in 4
participants with AD and 1 unaffected relative with an unspecified age in gene-resequencing studies
targeting TREM24,49,50 is rarer than the well-documented R47H variant that has been associated
with increased risk of AD in several studies,4,51 including the ADSP cohort.7,8 Homozygosity of this
mutation causes Nasu-Hakola disease, a rare disorder characterized by early-onset dementia and
multifocal bone cysts,28 and has also been observed in a member of a Turkish family with
frontotemporal dementia–like syndrome, including the appearance of aggressive behavior and
generalized tonic-clonic seizures before age 30 years but without bone involvement.52 Because
persons with Nasu-Hakola disease and the frontotemporal dementia syndrome case have amore
severe phenotype overall andmuch earlier onset of dementia symptoms than participants with late-
onset ADwho are heterozygous for Q33X, the behavior of this mutation maymore resemble an
intermediate inheritance than an autosomal-dominant model. This idea is consistent with the
observation that both living parents of a patient with Nasu-Hakola disease whowere obligate Q33X
heterozygotes had evidence of β-amyloid deposition by cerebrospinal fluid analysis and florbetapir
positron emission tomographic imaging.52
Furthermore, unlike the TREM2 R47Hmutation and rare coding variants at other loci that have
been associated with AD,4-8 theNOTCH3 rs149307620 and TREM2Q33Xmutations appear to be fully
penetrant among persons surviving to late age, which perhapswould be the first examples of causative
mutations for late-onset AD. This assertion is somewhat speculative given the small number of
participants with AD documented to have thesemutations.
Our study also implicatedmultiple functional variants in several novel genes as risk factors for
AD. Mutations in ABCD4 cause an inborn error of vitamin B12 metabolism.
53 Vitamin B12 deficiency is
associated with cognitive impairment, and the level of circulating vitamin B12 has been associated
with AD risk.54 ABCD4 encodes an adenosine triphosphate–binding cassette transporter that is in the
same family as well-established AD gene ABCA7.39,40 The AD-associated CELSR1 rs61741871 (P2983A)
missense variant has also been associatedwith craniorachischisis, which is a severe neural tube defect,55
and other CELSR1 variants have been identified as ischemic stroke risk factors in Japanese individuals.56
The CELSR1-3 family of genes has multiple functions in the nervous system and distinct roles in brain
development andmaintenance.57 GTSE1 regulates G1/S cell cycle transition andmicrotubule stability
and is involved in pivotal neurodegeneration pathways.58 It is not clearwhich of theseCELSR1 andGTSE1
mutationsmay directly influenceAD risk. LAMC3 encodes laminin subunit γ 3, andmultiple experimental
studies have linked laminins to AD.59,60 LAMC3 has been significantly associated with age at onset
of AD.61
Limitations
Our study has several limitations. Because we focused on rare variants, our sample of more than
10000 participants was inadequate to establish statistical significance. Thus, our findings require
replication in independent samples. Wewere unable to replicate these findings in the Alzheimer’s
Disease Genetics Consortium genome-wide association study data set because of low and
inconsistent imputation quality for these rare variants, despite the use of the large Haplotype
Reference Consortium reference panel.62 In addition, our genome-wideMAC cutoffs for focusing on
particular variants were arbitrary and, therefore, some important findings may have been
overlooked.
It is possible that cryptic relatedness in the sample may have exaggerated some of our results;
however, among the highlighted findings, the largest pairwise IBD score of 0.11 (indicating an
association slightly more distant than first-cousins) was observed for 1 pair of NOTCH3mutation
carriers. Our scheme for selecting genes previously associated with AD, AD-related traits, or other
dementias omitted important loci that were reported after we completedmost of our analyses (eg,
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ADAM1763), ascertained through a connection to a nondementing illness (eg, TBK164), or do not have
variants linked to late-onset AD (eg, TYROBP65). In addition, because wewere unable to validate all
rare variants reported in this study owing, in part, to availability of specimens containing these
variants, some of the highlighted associations may be false-positives due to variant calling errors.
However, most of these variants, including TREM2Q33X and all of those in ABCD4, CELSR1, and
GTSE1, have been reported previously.21
Although one of the explicit goals of the ADSP is to identify variants that protect against AD,23
the design corresponding to the one we used to identify risk variants (ie, a controls-only analysis) is
less rigorous because, in the absence of statistically significant tests, it is difficult to demonstrate a
protective effect if the variant has reduced penetrance.
Conclusions
We observed associations with novel variants in previously established AD genes and with several
novel potential AD genes that did not emerge in previous analyses of a largeWES data set using
conventional statistical thresholds.7 Several of the results implicating novel AD genes—in particular,
ABCD4, CELSR1, GTSE1—merit further epidemiologic and experimental studies. Our findings with the
NOTCH3 and TREM2 variants suggest that mutations in the same gene can result in dissimilar types
of dementia. Moreover, a variable dose of a particular mutation (ie, TREM2Q33X) can cause different
types of dementia. These findings suggest that minor differences in protein structure or amount of
wild-type protein can result in different clinical outcomes. Understanding these genotype-
phenotype associations may provide further insight into the pathogenic nature of themutations, as
well as offer clues for developing new therapeutic targets.
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